Ask AI
ProCE Banner Activity

CME

Global Guidance and Regional Perspectives on Optimizing Molecular Profiling and Perioperative Management of Early-Stage NSCLC

Video

In this certified on-demand webcast, experts discuss best practices for optimizing timely molecular testing and biomarker interpretation to guide personalized perioperative treatment strategies for patients with early-stage NSCLC.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: June 11, 2026

Expiration: December 10, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for global medical oncologists, thoracic oncologists, pulmonologists, thoracic surgeons, pathologists, molecular biologists, and other healthcare professionals who care for patients with early-stage NSCLC.

Program Learning Goal

This activity aims to improve learners’ knowledge, confidence, and competence at performing timely comprehensive molecular testing to select the optimal systemic treatment for each patient with early-stage NSCLC. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate colleagues on the rationale and clinical utility of comprehensive molecular testing in early-stage NSCLC

  • Perform molecular testing in each patient with early-stage NSCLC consistent with current evidence and local expert guidance

  • Develop processes to optimize interdisciplinary communication and collaboration to ensure timely and accurate interpretation of molecular testing for each patient with early-stage NSCLC

  • Recommend the optimal targeted therapy or immunotherapy for each patient with early-stage NSCLC, considering molecular testing results, patient/disease factors, evidence, and local expert guidance

  • Appraise emerging evidence and ongoing clinical trials of novel targeted therapies and immunotherapies and the clinical implications for management of early-stage NSCLC

Financial Disclosures

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Jamie E. Chaft, MD: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, EMD Serono, Exact Sciences, Genentech/Roche, Guardant, Foundation Medicine, Natera, Nuvation Bio, Revolution; researcher (paid to institution): AstraZeneca, BioNtech, Boehringer Ingelheim, Bristol Myers Squibb, Genentech/Roche, Lilly, Merck, Taiho.

Fernando Lopez-Rios, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Lilly, MSD, Pfizer, Regeneron; researcher: AstraZeneca, Janssen, Lilly, Pfizer, Roche, Thermo Fisher.

Luis Paz-Ares, MD, PhD: honoraria: Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Jazz, Lilly, Merck Serono, Mirati, Novartis, Pfizer, PharmaMar, Roche/Genentech, Sanofi, Takeda; founder and board member: ALTUM Sequencing, Stab Therapeutics; research funding (to Institution): AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, PharmaMar; speaker: Bristol Myers Squibb, Lilly, Merck Serono, Merck Sharp & Dohme, Pfizer, Roche/Genentech.

Soo Ryum (Stewart) Yang, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Lilly, Merus, Revolution Medicines, Roche, Sanofi.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 11, 2026, through December 10, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Additional Disclosures

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.